Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Intrinsic Value
Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. [ Read More ]
The intrinsic value of one
CNTA
stock under the Base Case scenario is
3.85
USD.
Compared to the current market price of 8.93 USD,
Centessa Pharmaceuticals PLC
is
Overvalued by 57%.
CNTA's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
CNTA or that its price is influenced by factors unrelated to fundamentals.
Centessa Pharmaceuticals PLC's market capitalization is 882.1m USD.
CNTA stock price is 8.93 USD.
CNTA stock (3.85 USD) is 57% less than its price (8.93 USD).
CNTA. Open DCF Valuation
CNTA stock (3.85 USD) is 57% less than its price (8.93 USD). Open Relative Valuation
CNTA has upside potential of 55% compared to the average analyst price target.
Open Wall St Estimates
CNTA's ROE (Return on Equity) has significantly increased in the last 3 years from -89% to -53%, and is approaching profitability.
CNTA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -270% to -228%, and is approaching profitability.
CNTA has negative Operating Income for the last twelve months.
CNTA has negative Net Income for the last twelve months.
CNTA's ROE (Return on Equity) for the past 12 months is negative and is equal to -53%.
CNTA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -228%.
CNTA's Revenue is forecast to grow at a rate of 84% per year over the next 3 years.
CNTA's long-term assets (360m USD) exceed its long-term liabilties (124m USD).
CNTA's D/E (Debt to Equity) is very low and is equal to 0.32.
CNTA has negative Free Cash Flow for the last twelve months.
CNTA has negative Net Debt. This means that the company has more cash and short-term investments (257m USD) than debt (76m USD).
CNTA has negative three-year average ROE (Return on Equity): -52%. The company is not efficient at transforming stockholders' equity into net income.
CNTA has negative three-year average ROIC (Return on Invested Capital): -636%. The company is not efficient at using invested capital to generate operating income.
CNTA's short-term assets (315m USD) exceed its short-term liabilties (39m USD).
CNTA's Altman Z-Score is very low and is equal to -0.61.
CNTA doesn't generate enough operating income (-171m USD) to safely cover interest payments on its debt (10m USD).
Valuation Backtest
Centessa Pharmaceuticals PLC
Run backtest to discover the historical profit from buying and selling
CNTA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Centessa Pharmaceuticals PLC
Balance Sheet Decomposition
Centessa Pharmaceuticals PLC
| Current Assets | 315.1m |
| Cash & Short-Term Investments | 256.5m |
| Receivables | 39.1m |
| Other Current Assets | 19.4m |
| Non-Current Assets | 45.2m |
| PP&E | 13m |
| Other Non-Current Assets | 32.2m |
| Current Liabilities | 39.4m |
| Accounts Payable | 11.8m |
| Accrued Liabilities | 27.5m |
| Other Current Liabilities | 112k |
| Non-Current Liabilities | 84.6m |
| Long-Term Debt | 75.7m |
| Other Non-Current Liabilities | 8.9m |
Earnings Waterfall
Centessa Pharmaceuticals PLC
|
Revenue
|
6.9m
USD
|
|
Operating Expenses
|
-178.1m
USD
|
|
Operating Income
|
-171.3m
USD
|
|
Other Expenses
|
20.2m
USD
|
|
Net Income
|
-151.1m
USD
|
Free Cash Flow Analysis
Centessa Pharmaceuticals PLC
CNTA Profitability Score
Profitability Due Diligence
Centessa Pharmaceuticals PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Centessa Pharmaceuticals PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CNTA Solvency Score
Solvency Due Diligence
Centessa Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Centessa Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CNTA Price Targets Summary
Centessa Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
CNTA
is 13.87 USD
with a low forecast of 8.08 USD and a high forecast of 21 USD.
Ownership
CNTA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CNTA Price
Centessa Pharmaceuticals PLC
| Average Annual Return | -59.85% |
| Standard Deviation of Annual Returns | 18.58% |
| Max Drawdown | -88% |
| Market Capitalization | 882.1m USD |
| Shares Outstanding | 97 629 296 |
| Percentage of Shares Shorted | 2.35% |
Company Profile
Centessa Pharmaceuticals PLC
Country
Industry
Market Cap
Dividend Yield
Description
Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company is headquartered in Altrincham, Cheshire and currently employs 90 full-time employees. The company went IPO on 2021-05-28. The firm's asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa's clinical stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The firm's preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The firm's subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.
Contact
IPO
Employees
Officers
The intrinsic value of one
CNTA
stock under the Base Case scenario is
3.85
USD.
Compared to the current market price of 8.93 USD,
Centessa Pharmaceuticals PLC
is
Overvalued by 57%.
You don't have any saved screeners yet
